inclusion criteria: 1. adult participants: signed informed consent 2. new admission to hospital for period expected to last ≥ 1 night 3. suspected or confirmed covid-19 infection patients are suspected of covid-19 infection if they have the following: · influenza like illness (fever ≥37.8°c and at least one of the following respiratory symptoms, which must be of acute onset: persistent cough, hoarseness, nasal discharge or congestion, shortness of breath, sore throat, wheezing or sneezing). and · finding from either a chest x-ray or ct suggestive of covid-19 infection and · alternative causes are considered unlikely 4. for women to be eligible to enter and participate in the study they should be: of non-child-bearing * potential defined as either post-menopausal (12 months of spontaneous amenorrhea and ≥ 45 years of age) or physically incapable of becoming pregnant with documented tubal ligation, hysterectomy or bilateral oophorectomy or, * or of child-bearing potential have a negative pregnancy test at screening and agrees to remain sexually abstinent or use a method of contraception with a failure rate of \< 1% per year as indicated in appendix b during the treatment and for a period of 7 days after the last dose. hormonal contraceptive methods must be supplemented by a barrier method. 5. men who are sexually active must use an adequate method of contraception as listed in appendix b, for a period of at least 7 days after the last dose

inclusion criteria: 1. adult participants: signed informed consent 2. new admission to hospital for period expected to last ≥ 1 night 3. suspected or confirmed covid-19 infection patients are suspected of covid-19 infection if they have the following: · influenza like illness (fever ≥37.8°c and at least one of the following respiratory symptoms, which must be of acute onset: persistent cough, hoarseness, nasal discharge or congestion, shortness of breath, sore throat, wheezing or sneezing). and · finding from either a chest x-ray or ct suggestive of covid-19 infection and · alternative causes are considered unlikely 4. for women to be eligible to enter and participate in the study they should be: of non-child-bearing * potential defined as either post-menopausal (12 months of spontaneous amenorrhea and ≥ 45 years of age) or physically incapable of becoming pregnant with documented tubal ligation, hysterectomy or bilateral oophorectomy or, * or of child-bearing potential have a negative pregnancy test at screening and agrees to remain sexually abstinent or use a method of contraception with a failure rate of \< 1% per year as indicated in appendix b during the treatment and for a period of 7 days after the last dose. hormonal contraceptive methods must be supplemented by a barrier method. 5. men who are sexually active must use an adequate method of contraception as listed in appendix b, for a period of at least 7 days after the last dose

inclusion criteria: adult participants: signed informed consent new admission to hospital for period expected to last ≥ 1 night suspected or confirmed covid-19 infection patients are suspected of covid-19 infection if they have the following: · influenza like illness (fever ≥37.8°c and at least one of the following respiratory symptoms, which must be of acute onset: persistent cough, hoarseness, nasal discharge or congestion, shortness of breath, sore throat, wheezing or sneezing). and · finding from either a chest x-ray or ct suggestive of covid-19 infection and · alternative causes are considered unlikely for women to be eligible to enter and participate in the study they should be: of non-child-bearing potential defined as either post-menopausal (12 months of spontaneous amenorrhea and ≥ 45 years of age) or physically incapable of becoming pregnant with documented tubal ligation, hysterectomy or bilateral oophorectomy or, or of child-bearing potential have a negative pregnancy test at screening and agrees to remain sexually abstinent or use a method of contraception with a failure rate of < 1% per year as indicated in appendix b during the treatment and for a period of 7 days after the last dose. hormonal contraceptive methods must be supplemented by a barrier method. men who are sexually active must use an adequate method of contraception as listed in appendix b, for a period of at least 7 days after the last dose

inclusion criteria: adult participants: signed informed consent new admission to hospital for period expected to last ≥ 1 night suspected or confirmed covid-19 infection patients are suspected of covid-19 infection if they have the following: · influenza like illness (fever ≥37.8°c and at least one of the following respiratory symptoms, which must be of acute onset: persistent cough, hoarseness, nasal discharge or congestion, shortness of breath, sore throat, wheezing or sneezing). and · finding from either a chest x-ray or ct suggestive of covid-19 infection and · alternative causes are considered unlikely for women to be eligible to enter and participate in the study they should be: of non-child-bearing potential defined as either post-menopausal (12 months of spontaneous amenorrhea and ≥ 45 years of age) or physically incapable of becoming pregnant with documented tubal ligation, hysterectomy or bilateral oophorectomy or, or of child-bearing potential have a negative pregnancy test at screening and agrees to remain sexually abstinent or use a method of contraception with a failure rate of < 1% per year as indicated in appendix b during the treatment and for a period of 7 days after the last dose. hormonal contraceptive methods must be supplemented by a barrier method. men who are sexually active must use an adequate method of contraception as listed in appendix b, for a period of at least 7 days after the last dose

inclusion criteria: 1. adult participants: signed informed consent 2. new admission to hospital for period expected to last ≥ 1 night 3. suspected or confirmed covid-19 infection patients are suspected of covid-19 infection if they have the following: · influenza like illness (fever ≥37.8°c and at least one of the following respiratory symptoms, which must be of acute onset: persistent cough, hoarseness, nasal discharge or congestion, shortness of breath, sore throat, wheezing or sneezing). and · finding from either a chest x-ray or ct suggestive of covid-19 infection and · alternative causes are considered unlikely 4. for women to be eligible to enter and participate in the study they should be: of non-child-bearing - potential defined as either post-menopausal (12 months of spontaneous amenorrhea and ≥ 45 years of age) or physically incapable of becoming pregnant with documented tubal ligation, hysterectomy or bilateral oophorectomy or, - or of child-bearing potential have a negative pregnancy test at screening and agrees to remain sexually abstinent or use a method of contraception with a failure rate of < 1% per year as indicated in appendix b during the treatment and for a period of 7 days after the last dose. hormonal contraceptive methods must be supplemented by a barrier method. 5. men who are sexually active must use an adequate method of contraception as listed in appendix b, for a period of at least 7 days after the last dose

inclusion criteria: 1. adult participants: signed informed consent 2. new admission to hospital for period expected to last ≥ 1 night 3. suspected or confirmed covid-19 infection patients are suspected of covid-19 infection if they have the following: · influenza like illness (fever ≥37.8°c and at least one of the following respiratory symptoms, which must be of acute onset: persistent cough, hoarseness, nasal discharge or congestion, shortness of breath, sore throat, wheezing or sneezing). and · finding from either a chest x-ray or ct suggestive of covid-19 infection and · alternative causes are considered unlikely 4. for women to be eligible to enter and participate in the study they should be: of non-child-bearing - potential defined as either post-menopausal (12 months of spontaneous amenorrhea and ≥ 45 years of age) or physically incapable of becoming pregnant with documented tubal ligation, hysterectomy or bilateral oophorectomy or, - or of child-bearing potential have a negative pregnancy test at screening and agrees to remain sexually abstinent or use a method of contraception with a failure rate of < 1% per year as indicated in appendix b during the treatment and for a period of 7 days after the last dose. hormonal contraceptive methods must be supplemented by a barrier method. 5. men who are sexually active must use an adequate method of contraception as listed in appendix b, for a period of at least 7 days after the last dose